A pharmacy benefit manager may not discriminate against a pharmacy in a health plan that is a 340B entity, or against a pharmacy under contract with one.
Bill
HB 1137
Act
SL 2019, ch. 213
Session
2019
Applies to
Pharmacy benefit managers
Limits
Rewritten in 2024 by a later act, also listed here.
No pharmacy benefit manager may discriminate against a pharmacy participating in a health plan as an entity authorized to participate under section 340B of the Public Health Service Act, as amended to January 1, 2019, or any pharmacy under contract with such an entity to provide prescriptions
A pharmacy benefit manager or its affiliate may not discriminate against a 340B entity or its contract pharmacy: no lower payment, fees or chargebacks, network limits, required contracts, extra patient charges, limits on how drugs are dispensed or delivered, extra audits, or refusal to cover 340B drugs.
Act
SL 2024, ch. 203
Session
2024
In effect
1 January 2025
Applies to
Pharmacy benefit managers and their affiliates
Enforcement
A violator owes the 340B entity its actual and consequential damages, with attorneys' fees and costs.
Neither a pharmacy benefit manager nor a pharmacy benefit manager affiliate may, directly or indirectly, discriminate against a 340B entity or a pharmacy under contract with a 340B entity, on the basis that the 340B entity or a pharmacy under contract with a 340B entity participates in the 340B drug discount program by imposing terms or conditions that differ from a similarly situated entity that does not participate in the 340B drug discount program
A manufacturer may not deny, restrict or prohibit a 340B drug reaching a location that a 340B entity or pharmacy has authorized to receive it, and may not require claim or utilization data as a condition.
Bill
SB 154
Act
SL 2025, ch. 198
Session
2025
Applies to
Drug manufacturers
Limits
Does not require a manufacturer to give a 340B price to a pharmacy. Limited distribution required by 21 U.S.C. 355-1 is allowed. Audits under federal law are allowed.
Enforcement
A 340B entity or pharmacy may sue for an injunction, damages and attorneys' fees. A breach is also a deceptive act under section 37-24-6.
A pharmaceutical manufacturer may not, directly or indirectly, deny, restrict, or prohibit the acquisition of a 340B drug or the delivery of a 340B drug to a location that is authorized to receive the drug by a 340B entity or pharmacy, unless receipt of the 340B drug is prohibited by federal law
Plain-language summaries, not legal advice. Laws change, and court rulings on them are not covered here. Read the state’s own page before you rely on one.